Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPCR-Lip
- Development stage
- Preclinical
- Lead developer
- Sichuan Agricultural University
- Modality
- Small Molecules, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**OPCR-Lip** is an investigational chondroitin sulfate-modified liposomal fixed-dose anticancer formulation developed for solid tumors. It incorporates retinoic acid-functionalized liposomes, an MMP-2-responsive PD-L1 inhibitory D-peptide component based on D-PPA-1, and co-encapsulated oxaliplatin. The formulation is designed to target CD44-expressing tumor cells, block membrane PD-L1, disrupt Golgi-dependent PD-L1 glycosylation and exosomal PD-L1 secretion, and induce oxaliplatin-mediated immunogenic cell death. In preclinical 4T1 breast cancer, B16F10 melanoma, and Lewis lung carcinoma models, OPCR-Lip enhanced antitumor immune activity and tumor-growth control.
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on OPCR-Lip.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPCR-Lip.